Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
10.1097/MPA.0000000000001222 31 ZhuP.GeN.LiuD.YangF.ZhangK.GuoJ.et al (2018)
B., & Aronne, L
217 OConnorJCAndrCWangYLawsonMASzegediSSLestageJet al
Research Snapshot: Current State of Research Semaglutide has been examined extensively in GLP-1 receptor pharmacology, glucose-regulation research, appetite and gastric-emptying studies, cardiovascular-outcome research, body-weight trials, kidney-outcome research, and peptide-formulation studies
Considerations: Compounded medications may vary in formulation, potency, or stability, and their safety and effectiveness have not been reviewed by the FDA
These are consistent with the broader class of GLP-1-based therapies and include: Nausea the most commonly reported symptom, particularly during dose escalation Vomiting less frequent than nausea but reported, especially at higher doses Diarrhoea often transient and associated with early treatment phases Constipation some participants report alternating bowel habits Decreased appetite a desired pharmacological effect, though it can feel uncomfortable initially Belching and bloating related to slowed gastric emptying Additional effects reported with retatrutide or with medicines in the same class include: Injection-site reactions such as redness, itching, or mild discomfort at the injection site Headache and dizziness particularly during early treatment Small increases in heart rate modest elevations have been observed with GLP-1-based therapies
US$ 21.29
%20(1).png)
US$ 21.95
US$ 27.33
US$ 28.53
